These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25902723)

  • 21. The "hairy kidney" sign.
    Triffo WJ; Dyer RB
    Abdom Radiol (NY); 2017 Mar; 42(3):979-980. PubMed ID: 27841012
    [No Abstract]   [Full Text] [Related]  

  • 22. [Erdheim-Chester disease: an aggressive systemic disease treated with cladribine with favorable outcome (a case report)].
    Lasri N; Lahlimi F; Tazi MI
    Pan Afr Med J; 2022; 42():32. PubMed ID: 35910054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy].
    Král Z; Řehák Z; Krejčí M; Koukalová R; Ševčíková S; Pour L; Krejčí M; Štork M; Sandecká V; Adam Z
    Vnitr Lek; 2021; 67(3):157-164. PubMed ID: 34171955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha.
    Braiteh F; Boxrud C; Esmaeli B; Kurzrock R
    Blood; 2005 Nov; 106(9):2992-4. PubMed ID: 16020507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
    Schirmer JH; Thorns C; Moosig F; Holle JU
    Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
    [No Abstract]   [Full Text] [Related]  

  • 26. Erdheim-Chester disease: multisystem involvement and management with interferon-alpha.
    Suzuki HI; Hosoya N; Miyagawa K; Ota S; Nakashima H; Makita N; Kurokawa M
    Leuk Res; 2010 Jan; 34(1):e21-4. PubMed ID: 19679354
    [No Abstract]   [Full Text] [Related]  

  • 27. Erdheim-Chester disease in a child.
    Wen C; Liang Q; Yi Z; Wan W
    West Indian Med J; 2012 Nov; 61(8):834-7. PubMed ID: 23757907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Partial regression of CNS lesions of Erdheim-Chester disease after treatment with 2-chlorodeoxadenosine and their full remission following treatment with lenalidomide].
    Adam Z; Sprláková A; Rehák Z; Koukalová R; Szturz P; Krejcí M; Pour L; Zahradová L; Cervinek L; Kren L; Moulis M; Hermanová M; Mechl M; Prásek J; Hájek R; Král Z; Mayer J
    Klin Onkol; 2011; 24(5):367-81. PubMed ID: 22070019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of cutaneous-onset Erdheim-Chester disease with cobimetinib and anakinra.
    Aromolo IF; Moltrasio C; Maronese CA; Campochiaro C; Bonometti A; Berti E; Passoni E; Marzano A
    Clin Exp Dermatol; 2024 Apr; 49(5):523-525. PubMed ID: 38231013
    [No Abstract]   [Full Text] [Related]  

  • 30. A multiplication problem.
    Furlanetto TW; Fischer J; Polanczyk CA; Vasconcelos MV
    Am J Med; 2009 Jan; 122(1):32-4. PubMed ID: 19114169
    [No Abstract]   [Full Text] [Related]  

  • 31. Erdheim-Chester disease.
    Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
    Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erdheim-Chester disease: characteristics and management.
    Munoz J; Janku F; Cohen PR; Kurzrock R
    Mayo Clin Proc; 2014 Jul; 89(7):985-96. PubMed ID: 24814521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [An exophtalmos].
    Raffray L; Bertolotti A; Duffau P; Longueville E; Mercié P; Longy-Boursier M
    Presse Med; 2013 Dec; 42(12):1674-7. PubMed ID: 24144886
    [No Abstract]   [Full Text] [Related]  

  • 34. [Not Available].
    Mehdi ME; Regragui S; Eddou H; Jennane S; Maaroufi HE; Doghmi K; Mikdame M
    Pan Afr Med J; 2018; 29():62. PubMed ID: 29875943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interleukin-1 receptor blockade with anakinra provided cessation of fatigue, reduction in inflammation markers and regression of retroperitoneal fibrosis in a patient with Erdheim-Chester disease - case study and a review of literature].
    Adam Z; Szturz P; Bučková P; Cervinková I; Koukalová R; Rehák Z; Krejčí M; Pour L; Zahradová L; Hájek R; Král Z; Mayer J
    Vnitr Lek; 2012 Apr; 58(4):313-8. PubMed ID: 22559807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of anakinra treatment on cytokine and lymphocytes/ monocytes profile of an Erdheim-Chester patient.
    Sevčíková S; Kubiczková L; Sedlaříková L; Ríhová L; Kryukov F; Szturz P; Hajek R; Pour L; Adam Z
    Klin Onkol; 2014; 27(4):276-82. PubMed ID: 25115717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful Treatment of Erdheim-Chester Disease With Coronary Artery Involvement.
    Zhao AL; Wang YN; Wang FD; Niu N; Sun J; Mao YY; Zhou DB; Li J; Cao XX
    Can J Cardiol; 2018 Dec; 34(12):1688.e9-1688.e11. PubMed ID: 30527170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.
    Goyal G; Shah MV; Call TG; Litzow MR; Hogan WJ; Go RS
    JAMA Oncol; 2017 Sep; 3(9):1253-1256. PubMed ID: 28253394
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.
    Franconieri F; Martin-Silva N; de Boysson H; Galateau-Salle F; Emile JF; Bienvenu B; Aouba A
    Acta Oncol; 2016 Jul; 55(7):930-2. PubMed ID: 27031008
    [No Abstract]   [Full Text] [Related]  

  • 40. Erdheim-Chester disease.
    Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
    Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.